A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy

Jing Yang, Shilin Zhao, Jing Wang, Quanhu Sheng, Qi Liu, Yu Shyr

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


The ability to identify robust genomic signatures that predict response to immune checkpoint blockade is restricted by limited sample sizes and ungeneralizable performance across cohorts. To address these challenges, we established CancerImmu (http://bioinfo.vanderbilt.edu/database/Cancer-Immu/), a comprehensive platform that integrates large-scale multidimensional omics data, including genetic, bulk, and singlecell transcriptomic, proteomic, and dynamic genomic profiles, with clinical phenotypes to explore consistent and rare immunogenomic connections. Currently Cancer-Immu has incorporated data for 3,652 samples for 16 cancer types. It provides easy access to immunogenomic data and empowers researchers to translate omics datasets into biological insights and clinical applications. Significance:Cancer-Immu is a comprehensive functional portal for unraveling immune-genomic connections to improve immune checkpoint blockade-based cancer immunotherapy.

Original languageEnglish
Pages (from-to)539-542
Number of pages4
JournalCancer Research
Issue number4
Publication statusPublished - 2022 Feb 15

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy'. Together they form a unique fingerprint.

Cite this